drugset
drugset / Trial / NCT05425472

A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

NCT05425472 ↗

Phase 2 Unknown 30 enrolled Jiangsu HengRui Medicine Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy, safety and pharmacokinetic characteristics of HR070803 in the treatment of advanced esophageal cancer.

Timeline

Start
2022-07-27
Primary completion
2023-01-30
Completion
2023-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HR070803 Unknown — Intravenous

Indications

esophageal cancer